CLAIMS

~~1. A combination comprising an immune checkpoint inhibitor and a single-stranded antisense oligonucleotide targeted to STAT3 for use in the treatment of cancer, wherein the combination is to be administered to a patient in need thereof.~~

~~2. A combination for use according to claim 1, wherein the immune checkpoint inhibitor is selected from: an anti-PD-L1 antibody or an antigen-binding fragment thereof; an anti-PD1 antibody or an antigen-binding fragment thereof; and, an anti-CTLA-4 antibody or an antigen-binding fragment thereof.~~

~~3. A combination for use according to claim 1 or claim 2, wherein the immune checkpoint inhibitor is selected from: MEDI4736, MPDL3280A, 2.7A4, AMP-714, MDX-1105, nivolumab, pembrolizumab, pidilizumab, BMS936559, MPDL3280A, tremelimumab and ipilimumab.~~

~~4. A combination for use according to any one of claims 1 - 3, wherein the immune checkpoint inhibitor is MEDI4736.~~

~~5. A combination for use according to any of the previous claims wherein the single-stranded antisense oligonucleotide targeted to STAT3 does not inhibit STAT1, STAT4, or STAT6.~~

~~6. A combination for use according to any of the previous claims, wherein the single-stranded antisense oligonucleotide targeted to STAT3 is AZD9150.~~

~~7. A combination for use according to any of the previous claims, wherein the cancer is selected from: lung cancer, including non small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, hepatocellular carcinoma (HCC), head and neck cancer, including head and neck squamous cell carcinoma (HNSCC), and lymphoma, including diffuse large B-cell carcinoma (DLBCL).~~

~~8. A combination for use according to claim 7, wherein the cancer cells express PD-L1.~~

~~9. A combination for use according to any of the previous claims, wherein the cancer is PD-L1 positive.~~

~~10. A combination for use according to any of the previous claims wherein the immune checkpoint inhibitor is MEDI4736 and the single-stranded antisense oligonucleotide targeted to STAT3 is AZD9150.~~

~~11. A combination for use according to claim 10, wherein between about 1 mg/kg and 20 mg/kg MEDI4736, and between about 1 mg/kg and 10 mg/kg AZD9150 is to be administered to the patient.~~

~~12. A combination for use according to claim 11, wherein the treatment is to be administered every week, every 2 weeks, every 3 weeks, or every 4 weeks.~~

~~13. A combination for use according to any of the previous claims wherein the single-stranded antisense oligonucleotide targeted to STAT3 is to be administered to the patient before the immune checkpoint inhibitor.~~

~~14. A combination for use according to claim 13, wherein the single-stranded antisense oligonucleotide targeted to STAT3 is to be administered to the patient at least one day before the immune checkpoint inhibitor is to be administered to the patient.~~

~~15. A combination for use according to any one of claims 1 - 14, wherein the single-stranded antisense oligonucleotide targeted to STAT3 is AZD9150 and the immune checkpoint inhibitor is MEDI4736, and wherein AZD9150 and MEDI4736 are to be administered concurrently or at different times.~~

~~16. A combination for use according to any of the claims 1 - 15, wherein (i) two immune checkpoint inhibitors and (ii) a single-stranded antisense oligonucleotide targeted to STAT3 are to be administered to a patient in need thereof; wherein the two immune checkpoint inhibitors are MEDI4736 and tremelimumab, and the single-stranded antisense oligonucleotide targeted to STAT3 is AZD9150.~~

~~17. A pharmaceutical composition which comprises an immune checkpoint inhibitor and a single-stranded antisense oligonucleotide targeted to STAT3 in association with a pharmaceutically acceptable diluent or carrier for use in the treatmnet of cancer, wherein the pharmaceutical composition is to be administered to a patient in need thereof, wherein the patient has cancer.~~

1~~8~~. Use of ~~a combination comprising~~ an immune checkpoint inhibitor ~~and a single-stranded antisense oligonucleotide targeted to STAT3~~ in the manu~~a~~facture of a medicament for the treatment of cancer, wherein the ~~medicament is to be administered to a patient in need thereof, wherein the patient has cancer~~ immune checkpoint inhibitor is to be administered simultaneously, separately or sequentially in combination with a single-stranded antisense oligonucleotide targeted to STAT3.

2~~19~~. The use according to claim 1~~8~~, wherein the immune checkpoint inhibitor is selected from: an anti-PD-L1 antibody or an antigen-binding fragment thereof; an anti-PD1 antibody or an antigen-binding fragment thereof; and~~,~~ an anti-CTLA-4 antibody or an antigen-binding fragment thereof.

3~~20~~. The use according to claim 1~~8~~ or claim 2~~19~~, wherein the immune checkpoint inhibitor is selected from: MEDI4736, MPDL3280A, 2.7A4, AMP-714, MDX-1105, nivolumab, pembrolizumab, pidilizumab, BMS936559, MPDL3280A, tremelimumab and ipilimumab.

4~~21~~. The use according to any one of claims 1~~8~~ - 3~~20~~, wherein the immune checkpoint inhibitor is MEDI4736.

5~~22~~. The use according to any one of claims 1~~8~~ - 4~~21~~, wherein the single-stranded antisense oligonucleotide targeted to STAT3 does not inhibit STAT1, STAT4, or STAT6.

6~~23~~. The use according to any one of claims 1~~8~~ - 5~~22~~, wherein the single-stranded antisense oligonucleotide targeted to STAT3 is AZD9150.

7~~24~~. The use according to any one of claims 1~~8~~ - 6~~23~~, wherein the cancer is selected from: lung cancer, including non small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, hepatocellular carcinoma (HCC), head and neck cancer, including head and neck squamous cell carcinoma (HNSCC), and lymphoma, including diffuse large B-cell carcinoma (DLBCL).

8~~25~~. The use according to claim 7~~24~~, wherein the cancer cells express PD-L1.

9~~26~~. The use according to any one of claims 1~~8~~ - 8~~25~~, wherein the cancer is PD-L1 positive.

10~~27~~. The use according to any one of claims 1~~8~~ – 9~~26~~, wherein the immune checkpoint inhibitor is MEDI4736 and the single-stranded antisense oligonucleotide targeted to STAT3 is AZD9150.

11~~28~~. The use according to claim 10~~27~~, wherein between ~~about~~ 1 mg/kg and 20 mg/kg MEDI4736, and between ~~about~~ 1 mg/kg and 10 mg/kg AZD9150 is to be administered ~~to the patient~~.

12~~29~~. The use according to claim 11~~28~~, wherein the treatment is to be administered every week, every 2 weeks, every 3 weeks, or every 4 weeks.

13~~30~~. The use according to any one of claims 1~~8~~ – 12~~29~~, wherein the single-stranded antisense oligonucleotide targeted to STAT3 is to be administered ~~to the patient~~ before the immune checkpoint inhibitor.

1431. The use according to claim 1330, wherein the single-stranded antisense oligonucleotide targeted to STAT3 is to be administered ~~to the patient~~ at least one day before the immune checkpoint inhibitor is to be administered ~~to the patient~~.

1532. The use according to any one of claims 1~~8~~ – 1431, wherein the single-stranded antisense oligonucleotide targeted to STAT3 is AZD9150 and the immune checkpoint inhibitor is MEDI4736, and wherein AZD9150 and MEDI4736 are to be administered concurrently or at different times.

1633**.** The use according to any one of claims 1~~8~~ – 1532, wherein (i) two immune checkpoint inhibitors and (ii) a single-stranded antisense oligonucleotide targeted to STAT3 are to be administered ~~to a patient in need thereof~~; wherein the two immune checkpoint inhibitors are MEDI4736 and tremelimumab, and the single-stranded antisense oligonucleotide targeted to STAT3 is AZD9150.

1734. Use of a pharmaceutical composition which comprises an immune checkpoint inhibitor and a single-stranded antisense oligonucleotide targeted to STAT3 in association with a pharmaceutically acceptable diluent or carrier in the manu~~a~~facture of a medicament for the treatment of cancer, wherein the medicament is to be administered to a patient in need thereof, wherein the patient has cancer.